15.          Income Taxes

The components of income/(loss) before income taxes are as follows (in thousands):

  ​ ​ ​

Year Ended April 30,

 

2026

2025

2024

 

Domestic

$

(298,407)

$

68,814

$

68,968

Foreign

(7,215)

 

(29,150)

 

(5,737)

(Loss) income before income taxes

(305,622)

39,664

63,231

Equity method investment income (loss)

17,441

4,837

(1,674)

Total (loss) income before income taxes

$

(288,181)

$

44,501

$

61,557

The Company expects any foreign earnings to be reinvested in such foreign jurisdictions and, therefore, no deferred tax liabilities for U.S. income taxes on undistributed earnings are recorded. The foreign subsidiaries do not have any undistributed earnings.

A reconciliation of income tax expense/(benefit) computed using the U.S. federal statutory rates to actual income tax expense is as follows (dollars in thousands):

Year Ended April 30,

2026

2025

2024

Dollars

Percentages

Dollars

Percentages

Dollars

Percentages

U.S. federal statutory income tax rate

$

(64,181)

21.0

%

$

8,329

21.0

%

$

12,927

21.0

%

State income taxes, net of federal benefit

(4,558)

1.5

(987)

(2.5)

569

0.9

Effect of cross-border tax laws:

Foreign-derived intangible income

(7,830)

(19.7)

(9,831)

(16.0)

Tax Credits:

Research and development credits

(8,290)

2.7

(5,263)

(13.3)

(4,831)

(7.8)

Changes in valuation allowance

(2,665)

0.9

84

0.2

931

1.6

Nontaxable or nondeductible items:

Limit on executive compensation

5,958

(1.9)

2,646

6.7

1,687

2.7

Excess benefit relating to stock-based compensation

(5,040)

1.6

(2,997)

(7.6)

(389)

(0.6)

Goodwill impairment

44,438

(14.5)

Acquisition related costs

3,426

(1.1)

Other Perms

4,185

(1.5)

1,515

3.8

536

0.8

Changes in unrecognized tax benefit

2,321

(0.8)

459

1.2

(370)

(0.6)

Foreign Tax Effects:

Statutory tax rate different from US

(719)

0.2

(2,603)

(6.6)

(293)

(0.5)

Goodwill impairment

5,477

13.8

Change in valuation allowance

1,653

(0.5)

2,213

5.6

Other Adjustments

413

(0.1)

(161)

(0.4)

955

1.5

Effective income tax rate

$

(23,059)

7.5

%

$

882

2.2

%  

$

1,891

3.0

%

The components of the (benefit from) provision for income taxes are as follows (in thousands):

Year Ended April 30,

 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2024

 

Current:

Federal

$

(349)

$

21,901

$

20,990

State

 

3,896

 

(320)

 

1,511

Foreign

523

(76)

 

4,070

 

21,581

 

22,425

Deferred:

Federal

 

(19,494)

 

(19,301)

 

(18,844)

State

 

(7,635)

 

(734)

 

(625)

Foreign

(664)

(1,065)

 

(27,129)

 

(20,699)

 

(20,534)

Total income tax expense (benefit)

$

(23,059)

$

882

$

1,891

Significant components of the Company’s deferred income tax assets and liabilities are as follows (in thousands):

April 30,

 

  ​ ​ ​

2026

  ​ ​ ​

2025

 

Deferred income tax assets:

Accrued expenses

$

6,435

$

2,367

Stock based compensation

5,467

3,728

Allowances, reserves, and other

 

564

 

Unrealized loss on securities

 

1,704

 

3,787

Net operating loss and credit carry-forwards

 

75,001

 

21,620

163(J) disallowed interest expense carry-forward

28,083

Acquisition related costs

6,263

4,299

Capitalized research and development costs

59,288

57,266

Reserve for inventory excess and obsolescence

 

8,257

 

6,306

Lease liability

30,436

8,226

Total deferred income tax assets

 

221,498

 

107,599

Deferred income tax liabilities:

Fixed asset basis

 

(22,416)

 

(3,160)

Allowances, reserves, and other

(5,517)

(1,895)

Outside basis difference

(38)

(38)

Right-of-use asset

(28,749)

(7,645)

Intangibles basis

(185,053)

(6,631)

Total deferred income tax liabilities

 

(241,773)

 

(19,369)

Valuation allowance

 

(30,219)

 

(26,770)

Net deferred tax assets

$

(50,494)

$

61,460

The One Big Beautiful Bill Act was enacted in the U.S. on July 4, 2025. OBBBA introduced significant changes to the U.S. federal corporate tax system, including reinstating the immediate deductibility of domestic research and experimental (“R&E”) expenditures for tax years beginning after December 31, 2024. While foreign R&E expenditures continue to be capitalized and amortized over the applicable recovery period. Accordingly, the provisions impacting the Company have been reflected in the financial statements for the year ended April 30, 2026.

At April 30, 2026 and 2025 the Company recorded a valuation allowance of $30,219,000 and $26,770,000, respectively, against state net operating losses and state R&D credits as the Company is currently generating more tax credits than it will utilize in future years. The valuation allowance increased by $3,449,000 and $2,935,000 for April 30, 2026 and April 30, 2025, respectively, primarily due to state net operating losses and foreign deferred tax assets.

At April 30, 2026, the Company had federal R&D Credit carryforwards of 11,811,000, which carryforward to fiscal year 2046. At April 30, 2026, the Company had California R&D credit carryforwards of $21,425,000. These credits carryforward indefinitely.

At April 30, 2026, the Company had federal, state and foreign net operating loss carryforwards of approximately $180,315,000, $170,408,000 and $11,118,000, respectively. The federal net operating losses carry forward indefinitely. The state net operating losses will begin expiring in fiscal year 2036, and foreign net operating losses carry forward indefinitely. Utilization of federal and state net operating loss carryforwards may be subject to substantial annual limitation due to the ownership changes as provided by Section 382 of the Internal Revenue Code and similar state provisions.

At April 30, 2026 and 2025, the Company had approximately $16,196,000 and $13,429,000, respectively, of unrecognized tax benefits. Of the 2026 balance, $8,852,000 would impact the Company’s tax expense and $7,414,000 would result in an increase in California R&D credit valuation allowance. The Company estimates that $1,268,000 of its unrecognized tax benefits will decrease in the next twelve months due to statute of limitation expiration.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended April 30, 2026 and 2025 (in thousands):

April 30,

 

  ​ ​ ​

2026

  ​ ​ ​

2025

 

Balance as of May 1

$

13,429

$

13,601

Increases related to prior year tax positions

 

62

 

30

Decreases related to prior year tax positions

 

(141)

 

(18)

Increases related to current year tax positions

 

3,588

 

1,582

Decreases related to lapsing of statute of limitations

 

(742)

 

(1,766)

Balance as of April 30

$

16,196

$

13,429

The Company records interest and penalties on uncertain tax positions to income tax expense. As of April 30, 2026 and 2025, the Company had accrued approximately $1,609,000 and $454,000, respectively, of interest and penalties related to uncertain tax positions. The 2021 to 2024 tax years remain open to examination by the IRS for federal income taxes. The tax years 2019 to 2024 remain open for major state taxing jurisdictions.

The following table summarized income taxes paid for the year ended April 30, 2026, 2025 and 2024 (in thousands):

Year Ended April 30,

Year Ended April 30,

Year Ended April 30,

 

2026

  ​ ​ ​

2025

  ​ ​ ​

2024

 

Federal

$

2,250

$

24,175

$

17,387

State:

Alabama

 

(272)

 

 

California

514

Florida

 

351

 

 

Maryland

204

Other

 

174

 

682

 

2,533

Foreign:

 

 

 

Germany

385

(226)

518

Total income taxes paid

$

3,606

$

24,631

$

20,438

Free Sentinel

Want the next AeroVironment Inc income taxes disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment AeroVironment Inc's next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2026Jun 29, 2026Showing above
2025Jun 25, 2025
2024Jun 27, 2024
2023Jun 28, 2023
2022Jun 29, 2022
2021Jun 29, 2021
2020Jun 24, 2020
2019Jun 26, 2019
2018Jun 27, 2018
2017Jun 28, 2017
2016Jun 29, 2016

About Income Taxes Disclosures

The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.

Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.